Finance da Vinci, ROSA, Mako, and other robotic surgery systems, $500K to $2.5M+.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.
Trusted by 1,000+ businesses nationwide
"I've worked with Brobas for a long time. They provided financing with a minimal down payment, which was crucial for me. Since then, I've grown with them and plan to open a fourth location."
Nikola T.
Fleet Owner
"The first day after submitting documents, they gave me a full breakdown of my situation and explained the strategy. I got a great offer, and now the truck works for me, not the other way around."
Oleh O.
Owner-Operator
"Brobas has great relationships with banks. The monthly payment they offered was comparable, if not lower, than equipment financing. You won't get the same terms walking into a street bank."
Natalya P.
Business Owner
Robotic surgery systems represent the cutting edge of surgical technology, and a major competitive advantage for hospitals and surgical centers. Whether you're acquiring an Intuitive da Vinci Xi for general and urological surgery, a Zimmer Biomet ROSA for orthopedic procedures, or a Stryker Mako for joint replacement, Brobas Capital Partners connects you with healthcare-specialized lenders who understand the revenue impact and clinical value of robotic surgery platforms.
Finance surgical robots from $500K to $2.5M+ with terms up to 84 months.
Lenders evaluate your surgical volume, case mix, and reimbursement rates, not just credit scores.
Bundle installation, surgeon training, service contracts, and instrument costs into financing.
Structured financing that allows technology upgrades as new robotic platforms are released.
Fill out a quick 5-minute application. No impact on your credit score.
Our AI engine matches you with the best lenders from our 500+ network.
Review competitive offers with transparent rates and terms.
Choose your best option and receive funding, often within days.
• $2,200,000 Intuitive da Vinci Xi System, Community hospital, 25 years operating, 760 credit. 5.24% APR, 84 months, 5% down. Includes installation, training, and first-year service contract.
• $950,000 Stryker Mako SmartRobotics, Orthopedic surgery center, 12 years, 730 credit. 5.49% APR, 72 months, $0 down.
• $1,500,000 da Vinci SP (Single-Port), Multi-hospital system adding urology robotic program, 745 credit. 5.24% APR, 84 months, MLA structure.
• $650,000 Zimmer Biomet ROSA Knee, Orthopedic ASC, 8 years operating, 715 credit. 5.74% APR, 72 months, 10% down.
Surgeon Recruitment: Robotic capability is now a top-3 factor for surgeons choosing where to practice. Hospitals without robotics risk losing their best surgeons to competitors.
Patient Demand: Patients increasingly research and request robotic surgery. Hospitals with robotic programs report 20-40% increases in surgical volume from new patient acquisition.
Clinical Outcomes: Robotic surgery consistently demonstrates shorter hospital stays (1-2 fewer days), lower complication rates, less blood loss, and faster return to normal activity. These outcomes translate to better quality metrics, higher CMS ratings, and improved payer negotiations.
Financial Impact: While the upfront cost is significant, the revenue impact is substantial. A hospital performing 200 robotic cases/year at an average reimbursement premium of $3,000 per case generates $600,000 in incremental revenue. Combined with reduced length of stay and lower complication costs, most systems achieve positive ROI within 24-36 months.
The Intuitive da Vinci Xi system costs approximately $1.5M-$2.5M. The da Vinci SP (single-port) is approximately $1.5M-$2M. Annual service contracts add $150K-$200K. Per-case instrument costs are $700-$3,500 per procedure.
Hospitals performing 150+ robotic cases/year typically see positive ROI within 2-3 years. Robotic surgery reduces average length of stay by 1-2 days, reduces readmissions, and attracts higher-acuity cases. Many hospitals report surgical volume increases of 20-40% after adding robotic capability.
Yes. ASCs performing robotics is a growing trend, especially for urological and gynecological procedures. We have lenders experienced with ASC financing models and the unique revenue patterns of outpatient surgical facilities.
Absolutely. The Stryker Mako ($800K-$1.2M), Zimmer Biomet ROSA ($600K-$1M), and Smith+Nephew CORI ($400K-$700K) are all equipment types we frequently finance.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.